BIOMAT Database Logo BIOMAT Database Logo

Effect of piroxicam therapy on granulocyte function and granulocyte elastase concentration in peripheral blood and synovial fluid of rheumatoid arthritis patients. 1989

C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Dipartimento di Medicina Interna e Terapia Medica, Università di Pavia-IRCCS Policlinico S. Matteo, Italy.

The effect of piroxicam therapy (20 mg/day for 15 days) on various polymorphonuclear granulocyte (PMN) responses and on PMN elastase concentration was investigated in nine patients with active rheumatoid arthritis. Peripheral blood and synovial fluid samples were collected before starting therapy and 12 h after the last dose of the drug. All patients were evaluable for peripheral blood analysis and six for synovial fluid analysis. Piroxicam therapy had no effect on PMN random migration and phagocytosis, while it significantly reduced both FMLP-induced aggregation and FMLP-induced chemotaxis. This seems mainly due to an effect on FMLP binding, as no differences were observed after therapy in PMA- and PHA-induced aggregation as well as in serum-induced chemotaxis. In contrast, a marked impairment of NBT test and PMA- and FMLP-induced superoxide anion (O2-) production was found after piroxicam therapy. This effect was as evident in peripheral blood as in synovial fluid PMN. Also, a significant reduction in synovial fluid PMN number and synovial fluid PMN elastase concentration (elastase-alpha 1-proteinase complex) was found after treatment. It is concluded that piroxicam may act at different sites on various PMN responses. Its effect on O2- generation and PMN elastase concentration in synovial fluid may have an important role in reducing destruction of arthritic joint tissue.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D010894 Piroxicam A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. CP-16171,Feldene,CP 16171,CP16171
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D002449 Cell Aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type. Aggregation, Cell,Aggregations, Cell,Cell Aggregations
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D005260 Female Females

Related Publications

C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Cathepsin G and elastase in synovial fluid and peripheral blood in reactive and rheumatoid arthritis.
January 1996, Clinical rheumatology,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Immunoreactive granulocyte elastase in rheumatoid synovial fluid and membrane.
January 1982, Scandinavian journal of plastic and reconstructive surgery,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
[The effect of combined therapy on the ortofen concentration of the blood plasma and synovial fluid in patients with rheumatoid arthritis].
July 1999, Likars'ka sprava,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Binding of piroxicam to synovial fluid and plasma proteins in patients with rheumatoid arthritis.
January 1984, European journal of clinical pharmacology,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis.
January 1982, Journal of immunology (Baltimore, Md. : 1950),
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Detection of granulocyte elastase specific IgG split products in rheumatoid synovial fluid.
January 1988, Advances in experimental medicine and biology,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Immunological characteristics of lymphocytes in synovial fluid and peripheral blood in patients with rheumatoid arthritis.
January 1978, Archivum immunologiae et therapiae experimentalis,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis.
July 1991, Journal of clinical immunology,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis.
October 1982, Annals of the rheumatic diseases,
C Montecucco, and A Mazzone, and D Pasotti, and R Caporali, and M Longhi, and D Casilli, and G Ricevuti, and P Fratino, and M P Ruffilli
Skewness of TCR Vβ of peripheral blood and synovial fluid of patients with rheumatoid arthritis.
January 2014, Journal of immunoassay & immunochemistry,
Copied contents to your clipboard!